X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for sepsis and complicated/uncomplicated urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for sepsis and complicated/uncomplicated urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
The collaboration aims to focus on the clinical advancement of RECCE 327 (R327). Currently it is being evaluated in the clinical trial studies for the treatment of Urinary tract infections including urosepsis.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Murdoch Children’s Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 29, 2024
Details:
RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Diabetic Foot Infections.
Lead Product(s): R327
Therapeutic Area: Podiatry Product Name: RECCE 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Through collaboration, Reece will focus on the clinical development of RECCE 327 (r327), a new class of anti-infective. It is being evaluated in clinical trial studies for the treatment of urinary tract infections including urosepsis.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PT Etana Biotechnologies Indonesia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 07, 2024
Details:
RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Diabetic Foot Infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
R327 (RECCE-327) is a fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including their resistant forms. It is under preclinical development for the treatment of Gonorrhea.
Lead Product(s): RECCE-327
Therapeutic Area: Infections and Infectious Diseases Product Name: R327
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for sepsis and complicated/uncomplicated urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
RECCE® 327 is an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including Urinary Tract Infections and Urosepsis.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
